Spots Global Cancer Trial Database for refractory anemia

Every month we try and update this database with for refractory anemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies	NCT01175785	Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Myelo...	umbilical cord ... fludarabine pho... cyclophosphamid... ex vivo-expande... total-body irra... cyclosporine mycophenolate m... laboratory biom...	6 Months - 45 Years	Nohla Therapeutics, Inc.
Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome	NCT00003171	Leukemia Myelodysplastic...	bryostatin 1	18 Years -	Barbara Ann Karmanos Cancer Institute
Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome	NCT00005598	Myelodysplastic...	amifostine trih... azacitidine	18 Years -	University of Michigan Rogel Cancer Center
Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome	NCT00003123	Myelodysplastic...	amifostine trih...	17 Years -	National Cancer Institute (NCI)
Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome	NCT00017550	Myelodysplastic...	anti-thymocyte ...	18 Years - 120 Years	Sanofi
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia	NCT00003619	Chronic Myelopr... Leukemia Myelodysplastic... Thrombocytopeni...	filgrastim vitamin E busulfan cytarabine etoposide fludarabine pho... isotretinoin topotecan hydro... bone marrow abl... peripheral bloo...	19 Years - 90 Years	National Cancer Institute (NCI)
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia	NCT00357565	Leukemia Myelodysplastic... Childhood Acute... Recurrent Child... Secondary Acute... Childhood Acute... Previously Trea... Secondary Myelo... Refractory Anem... Refractory Anem... Refractory Anem... De Novo Myelody... Childhood Myelo...	filgrastim busulfan cyclosporine fludarabine pho... melphalan mycophenolate m... umbilical cord ...	- 3 Years	Masonic Cancer Center, University of Minnesota
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases	NCT00376519	Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo...	cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra...	18 Years - 45 Years	Masonic Cancer Center, University of Minnesota
Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes	NCT00398047	Leukemia Myelodysplastic...	Azacitadine and...	- 120 Years	Wake Forest University Health Sciences
Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome	NCT00004208	Myelodysplastic...	ATG + CSA Supportive care	18 Years -	Swiss Group for Clinical Cancer Research
Gemtuzumab in Treating Patients With Myelodysplastic Syndrome	NCT00022321	Myelodysplastic...	gemtuzumab ozog...	18 Years -	National Cancer Institute (NCI)
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy	NCT00891137	Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic...	human myeloid p...	12 Years - 65 Years	Cellerant Therapeutics
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes	NCT00234000	Leukemia Myelodysplastic...	arsenic trioxid... azacitidine	18 Years -	Jonsson Comprehensive Cancer Center
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers	NCT04083170	Acute Erythroid... Acute Lymphobla... Acute Megakaryo... Acute Myeloid L... Chronic Myeloge... Hematopoietic a... HIV Infection Myelodysplastic... Myelodysplastic... Non-Hodgkin Lym... Refractory Anem...	Fludarabine Cyclophosphamid... Thiotepa Total-Body Irra... Umbilical Cord ... Dilanubicel	6 Months - 65 Years	Fred Hutchinson Cancer Center
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer	NCT00027820	Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Myelo... Childhood Renal... Chronic Myelomo... Clear Cell Rena... de Novo Myelody... Metastatic Rena... Previously Trea... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Chil... Refractory Chro... Renal Medullary... Type 1 Papillar... Type 2 Papillar... Untreated Adult... Untreated Adult... Untreated Child...	Fludarabine Pho... Total-Body Irra... Peripheral Bloo... Nonmyeloablativ... Cyclosporine Mycophenolate M...	-	Fred Hutchinson Cancer Center
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	NCT02566304	Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto...	Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom...	18 Years -	Thomas Jefferson University
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia	NCT00392353	Acute Erythroid... Acute Megakaryo... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Myelodysplastic... Myelodysplastic... Recurrent Adult... Refractory Anem...	Azacitidine Laboratory Biom... Pharmacological... Vorinostat	18 Years -	National Cancer Institute (NCI)
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome	NCT00024050	Leukemia Myelodysplastic...	busulfan cyclophosphamid... cyclosporine methotrexate allogeneic bone... peripheral bloo...	- 65 Years	Fred Hutchinson Cancer Center
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases	NCT00003662	Graft Versus Ho... Leukemia Myelodysplastic... Thymic Carcinom...	anti-thymocyte ... busulfan cyclophosphamid... cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera...	-	Roswell Park Cancer Institute
Paricalcitol in Treating Patients With Myelodysplastic Syndrome	NCT00064376	Leukemia Myelodysplastic...	paricalcitol	25 Years - 100 Years	Cedars-Sinai Medical Center
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders	NCT03314974	Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M...	HSCT with TBI R... HSCT with Non-T...	- 60 Years	Masonic Cancer Center, University of Minnesota
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation	NCT00005641	Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic...	anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera...	15 Years - 60 Years	H. Lee Moffitt Cancer Center and Research Institute
Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes	NCT00997243	Leukemia Myelodysplastic...	lintuzumab 5-azacytidine	18 Years -	Ohio State University Comprehensive Cancer Center
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers	NCT04083170	Acute Erythroid... Acute Lymphobla... Acute Megakaryo... Acute Myeloid L... Chronic Myeloge... Hematopoietic a... HIV Infection Myelodysplastic... Myelodysplastic... Non-Hodgkin Lym... Refractory Anem...	Fludarabine Cyclophosphamid... Thiotepa Total-Body Irra... Umbilical Cord ... Dilanubicel	6 Months - 65 Years	Fred Hutchinson Cancer Center
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia	NCT00002926	Leukemia Myelodysplastic...	cytarabine etoposide idarubicin allogeneic bone... peripheral bloo...	16 Years - 60 Years	National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome	NCT00003959	Leukemia Myelodysplastic...	ras peptide can... sargramostim	17 Years -	Memorial Sloan Kettering Cancer Center
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders	NCT03314974	Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M...	HSCT with TBI R... HSCT with Non-T...	- 60 Years	Masonic Cancer Center, University of Minnesota
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome	NCT00002798	Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Anem... Secondary Myelo... Untreated Child...	asparaginase daunorubicin hy... fludarabine pho... therapeutic hyd... allogeneic bone... 3-dimensional c... filgrastim cytarabine idarubicin dexamethasone thioguanine etoposide methotrexate cyclophosphamid... aldesleukin busulfan	- 21 Years	National Cancer Institute (NCI)
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders	NCT00397813	Atypical Chroni... Chronic Myelomo... de Novo Myelody... Essential Throm... Myeloproliferat... Paroxysmal Noct... Polycythemia Ve... Polycythemia Ve... Primary Myelofi... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto...	Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Total-Body Irra...	50 Years - 75 Years	Fred Hutchinson Cancer Center
Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome	NCT00005598	Myelodysplastic...	amifostine trih... azacitidine	18 Years -	University of Michigan Rogel Cancer Center
Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant	NCT00376480	Leukemia Myelodysplastic...	anti-thymocyte ... peripheral bloo... fludarabine pho... methylprednisol... thiotepa allogeneic hema... in vitro-treate... total-body irra...	- 50 Years	Dana-Farber Cancer Institute
Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes	NCT00003138	Anemia Myelodysplastic...	Erythropoietin Filgrastim Transfusion	18 Years -	Eastern Cooperative Oncology Group
Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML	NCT00854945	Myelodysplastic... Acute Myeloid L...	ON 01910.Na	18 Years -	Traws Pharma, Inc.
Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer	NCT00295880	Myeloproliferat... Leukemia Lymphoma Myelodysplastic...	umbilical cord ...	12 Years - 45 Years	Masonic Cancer Center, University of Minnesota
Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia	NCT01146210	Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Fanconi Anemia Refractory Anem... Refractory Anem... Refractory Anem... Refractory Anem... Secondary Myelo... Untreated Child...	laboratory biom...	- 21 Years	Children's Oncology Group
Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant	NCT00376480	Leukemia Myelodysplastic...	anti-thymocyte ... peripheral bloo... fludarabine pho... methylprednisol... thiotepa allogeneic hema... in vitro-treate... total-body irra...	- 50 Years	Dana-Farber Cancer Institute
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT	NCT01012492	AML ALL Undifferentiate... Biphenotypic Le... Refractory Anem... Refractory Anem... Refractory Cyto... Ref. Cytopenia ... Refractory Anem... Refractory Anem... Myelodysplastic... MDS Associated ...	Abatacept	12 Years -	Boston Children's Hospital
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers	NCT04083170	Acute Erythroid... Acute Lymphobla... Acute Megakaryo... Acute Myeloid L... Chronic Myeloge... Hematopoietic a... HIV Infection Myelodysplastic... Myelodysplastic... Non-Hodgkin Lym... Refractory Anem...	Fludarabine Cyclophosphamid... Thiotepa Total-Body Irra... Umbilical Cord ... Dilanubicel	6 Months - 65 Years	Fred Hutchinson Cancer Center
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	NCT02566304	Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto...	Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom...	18 Years -	Thomas Jefferson University
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome	NCT00024050	Leukemia Myelodysplastic...	busulfan cyclophosphamid... cyclosporine methotrexate allogeneic bone... peripheral bloo...	- 65 Years	Fred Hutchinson Cancer Center
S0020 Immunosuppressive Therapy in Treating Patients With Myelodysplastic Syndrome	NCT00016419	Leukemia Myelodysplastic...	anti-thymocyte ... cyclosporine	15 Years -	SWOG Cancer Research Network
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer	NCT00012376	Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... Chronic Phase C... Paroxysmal Noct... Previously Trea... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Thrombocytopeni... Untreated Adult...	bryostatin 1 sargramostim laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders	NCT00397813	Atypical Chroni... Chronic Myelomo... de Novo Myelody... Essential Throm... Myeloproliferat... Paroxysmal Noct... Polycythemia Ve... Polycythemia Ve... Primary Myelofi... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto...	Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Total-Body Irra...	50 Years - 75 Years	Fred Hutchinson Cancer Center
Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes	NCT00104962	Childhood Myelo... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Myelo... Unspecified Chi...	lenalidomide	1 Year - 21 Years	National Cancer Institute (NCI)
Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome	NCT00731328	Leukemia Myelodysplastic... Nonmalignant Ne... Paroxysmal Noct...	nonmyeloablativ...	- 75 Years	Asan Medical Center
Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome	NCT00003681	Anemia Myelodysplastic...	epoetin alfa amifostine trih...	18 Years -	National Cancer Institute (NCI)
Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome	NCT00513578	Myelodysplastic...	PR1 leukemia pe... incomplete Freu... sargramostim	18 Years -	National Cancer Institute (NCI)
Topotecan in Treating Patients With Myelodysplastic Syndrome	NCT00003675	Leukemia Myelodysplastic...	topotecan hydro...	15 Years - 120 Years	Alliance for Clinical Trials in Oncology
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia	NCT00002926	Leukemia Myelodysplastic...	cytarabine etoposide idarubicin allogeneic bone... peripheral bloo...	16 Years - 60 Years	National Cancer Institute (NCI)
Decitabine in Treating Patients With Myelodysplastic Syndrome	NCT00003361	Leukemia Myelodysplastic...	decitabine	15 Years -	National Cancer Institute (NCI)
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	NCT02566304	Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto...	Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom...	18 Years -	Thomas Jefferson University
Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes	NCT00003138	Anemia Myelodysplastic...	Erythropoietin Filgrastim Transfusion	18 Years -	Eastern Cooperative Oncology Group
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT	NCT01012492	AML ALL Undifferentiate... Biphenotypic Le... Refractory Anem... Refractory Anem... Refractory Cyto... Ref. Cytopenia ... Refractory Anem... Refractory Anem... Myelodysplastic... MDS Associated ...	Abatacept	12 Years -	Boston Children's Hospital
Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes	NCT00104962	Childhood Myelo... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Myelo... Unspecified Chi...	lenalidomide	1 Year - 21 Years	National Cancer Institute (NCI)
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases	NCT00003662	Graft Versus Ho... Leukemia Myelodysplastic... Thymic Carcinom...	anti-thymocyte ... busulfan cyclophosphamid... cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera...	-	Roswell Park Cancer Institute
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy	NCT00891137	Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic...	human myeloid p...	12 Years - 65 Years	Cellerant Therapeutics
Decitabine in Treating Patients With Myelodysplastic Syndrome	NCT00003361	Leukemia Myelodysplastic...	decitabine	15 Years -	National Cancer Institute (NCI)
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases	NCT00309842	Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Myelofibrosis MDS Refractory Anem... Chronic Lymphoc... Prolymphocytic ... Non-Hodgkin's L... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	filgrastim cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... total-body irra...	- 55 Years	Masonic Cancer Center, University of Minnesota
Bortezomib in Treating Patients With Myelodysplastic Syndromes	NCT00262873	Myelodysplastic...	bortezomib	18 Years -	University of Rochester
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases	NCT00376519	Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo...	cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra...	18 Years - 45 Years	Masonic Cancer Center, University of Minnesota
Tipifarnib in Treating Patients With Myelodysplastic Syndromes	NCT00005845	Chronic Myelomo... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto...	tipifarnib laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Biological Therapy in Treating Patients With Myelodysplastic Syndrome	NCT00005853	Leukemia Myelodysplastic...	anti-thymocyte ... etanercept	-	Fred Hutchinson Cancer Center
Biological Therapy in Treating Patients With Myelodysplastic Syndrome	NCT00005853	Leukemia Myelodysplastic...	anti-thymocyte ... etanercept	-	Fred Hutchinson Cancer Center
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers	NCT00619645	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	busulfan cyclosporine fludarabine pho... mycophenolate m... allogeneic hema... peripheral bloo...	18 Years - 120 Years	University of California, Davis
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease	NCT00719888	Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... Burkitt Lymphom... Chronic Lymphoc... Chronic Myeloge... Chronic Phase C... Follicular Lymp... Lymphoblastic L... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... Myelofibrosis Non-Hodgkin Lym... Plasma Cell Mye... Prolymphocytic ... Refractory Anem... Small Lymphocyt...	Cyclophosphamid... Cyclosporine Double-Unit Umb... Fludarabine Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ... Thiotepa	6 Months - 45 Years	Fred Hutchinson Cancer Center
Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome	NCT00017550	Myelodysplastic...	anti-thymocyte ...	18 Years - 120 Years	Sanofi
Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome	NCT00003681	Anemia Myelodysplastic...	epoetin alfa amifostine trih...	18 Years -	National Cancer Institute (NCI)
Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes	NCT00997243	Leukemia Myelodysplastic...	lintuzumab 5-azacytidine	18 Years -	Ohio State University Comprehensive Cancer Center
Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer	NCT00004145	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	anti-thymocyte ... cyclophosphamid... fludarabine pho... peripheral bloo...	18 Years - 60 Years	University of Chicago

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: